• Xingxing Lv, Fusheng Gou, Yuan Shen, Hong Lu, Juan Chen, Juan Liu, Hui Chen, Xuan Zhang, and Danfei Yu.
• Department of Oncology and Hematology, People's Hospital of Leshan.
• Medicine (Baltimore). 2018 Nov 1; 97 (48): e13464e13464.

RationaleAdvanced non-small-cell lung cancer (NSCLC) is an aggressive malignancy that generally leads to poor outcomes, with <5% long-term survival at 5 years; however, several researches have shown improvements in the progression-free survival (PFS) and overall survival (OS) on the maintenance therapy after the first-line chemotherapy. we report a case of metastatic NSCLC patient treated with maintenance therapy of gemcitabine with brilliant results.Patient ConcernsClinical data and treatment of a 68-year-old man with NSCLC are summarized. The Ethics Committee of People's hospital of Leshan, approved this study.DiagnosisLung adenocarcinoma metastasized to the mediastinal lymph node, cervical lymph node, and adrenal gland, without epidermal growth factor receptor (EGFR) mutation.InterventionsContinued treatment with gemcitabine alone following the 6 cycles of cisplatin-gemcitabine chemotherapy, prolonging the interval of chemotherapy when he could not tolerate the toxicity of the drug.OutcomesPartial response of the disease for 4.5 years and significant clinical benefit.LessonsThis case shows that patients will benefit from the maintenance therapy, and gemcitabine may be a good choice.

19 keywords...

hide…